Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Advisory Services Network LLC

Advisory Services Network LLC boosted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 59.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 60,459 shares of the company's stock after purchasing an additional 22,648 shares during the period. Advisory Services Network LLC owned about 0.16% of Tarsus Pharmaceuticals worth $3,348,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of TARS. Capula Management Ltd acquired a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $354,000. Invesco Ltd. raised its holdings in Tarsus Pharmaceuticals by 36.7% in the 4th quarter. Invesco Ltd. now owns 932,115 shares of the company's stock worth $51,611,000 after purchasing an additional 250,018 shares during the period. Federated Hermes Inc. purchased a new position in Tarsus Pharmaceuticals during the fourth quarter worth approximately $4,303,000. Atika Capital Management LLC acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $9,812,000. Finally, Wells Fargo & Company MN increased its position in shares of Tarsus Pharmaceuticals by 44.1% in the fourth quarter. Wells Fargo & Company MN now owns 57,004 shares of the company's stock valued at $3,156,000 after buying an additional 17,451 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company's stock.

Insider Activity at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 3,084 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $154,539.24. Following the completion of the transaction, the general counsel now owns 51,712 shares in the company, valued at $2,591,288.32. The trade was a 5.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Dianne C. Whitfield sold 2,137 shares of the stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $107,085.07. Following the completion of the transaction, the insider now directly owns 46,355 shares in the company, valued at $2,322,849.05. This trade represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,542 shares of company stock valued at $1,581,173. 8.25% of the stock is owned by company insiders.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on TARS shares. Guggenheim reissued a "buy" rating and issued a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Jefferies Financial Group boosted their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Barclays cut their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Finally, HC Wainwright restated a "buy" rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $63.67.

Tarsus Pharmaceuticals Price Performance

Shares of Tarsus Pharmaceuticals stock traded up $0.37 on Tuesday, hitting $49.09. 213,317 shares of the company were exchanged, compared to its average volume of 680,282. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The company has a 50-day moving average price of $48.00 and a 200 day moving average price of $47.43. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -12.88 and a beta of 0.94. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. As a group, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.